Finance entity
markets is the sole category represented across all 1 tracked stories. Josh Brown is most often covered alongside FDA, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.3 in the same window.
Last mentioned: Mar 13, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets is the sole category represented across all 1 tracked stories. Josh Brown is most often covered alongside FDA, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 6.3 in the same window. Source depth averages 2 original sources per story, versus 2.3 across the same-window beat baseline. We currently track 1 Finance story that mention Josh Brown, all published on March 13, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 78 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Josh Brown. Shared-story counts are live from our verified record — not editorial picks.
Josh Brown argues that biotech growth stocks are uniquely positioned to withstand the disruption risks currently de-rating the software and services sectors. By leveraging AI to accelerate discovery while maintaining regulatory and patent moats, the sector offers a rare combination of high growth and structural stability.
Josh Brown is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
